Kellie J. Sims

Dr. Kellie J. Sims


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Women's Health Issues
Verified
Journal Article
Closed access
MBMackenzie C. Brown
Mackenzie C. Brown
KSKellie J. Sims
Kellie J. Sims
EGElizabeth J. Gifford
Elizabeth J. Gifford
KGKaren M. Goldstein
Karen M. Goldstein
MJMarcus R. Johnson
Marcus R. Johnson
DPDawn Provenzale
Dawn Provenzale

1 August 2021 in Life Sciences
Verified
Journal Article
Closed access
EGElizabeth J. Gifford
Elizabeth J. Gifford
JVJacqueline Vahey
Jacqueline Vahey
EHElizabeth R. Hauser
Elizabeth R. Hauser
KSKellie J. Sims
Kellie J. Sims
JEJimmy T. Efird
Jimmy T. Efird
DPDawn Provenzale
Dawn Provenzale

27 February 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
SASarah Tufael Ahmed
Sarah Tufael Ahmed
LSLea Steele
Lea Steele
PRPeter Richardson
Peter Richardson
SNShree Nadkarni
Shree Nadkarni
SBSandhya Bandi
Sandhya Bandi
DHDrew A. Helmer
Drew A. Helmer
Veterans with difficult-to-diagnose conditions who receive care in the Department of Veterans Affairs (VA) healthcare system can be referred for evaluation at one of three specialty VA War-Related Illness and Injury Study Centers (WRIISC). Veterans of the 1990–1991 Gulf War have long experienced excess rates of chronic symptoms associated with the condition known as Gulf War Illness (GWI), with hundreds evaluated at the WRIISC. Here we provide the first report from a cohort of 608 Gulf War Veterans seen at the WRIISC who completed questionnaires on chronic symptoms (>6 months) consistent with GWI as well as prominent exposures during Gulf War deployment. These included veterans’ reports of hearing chemical alarms/donning Military-Ordered Protective Posture Level 4 (MOPP4) gear, pesticide use, and use of pyridostigmine bromide (PB) pills as prophylaxis against the effects of nerve agents. Overall, veterans in the cohort were highly symptomatic and reported a high degree of exposures. In multivariable models, these exposures were significantly associated with moderate-to-severe chronic symptoms in neurocognitive/mood, fatigue/sleep, and pain domains. Specifically, exposure to pesticides was associated with problems with concentration and memory, problems sleeping, unrefreshing sleep, and joint pain. Use of MOPP4 was associated with light sensitivity and unrefreshing sleep and use of PB was associated with depression. We also evaluated the association of exposures with symptom summary scores based on veterans’ severity of symptoms in four domains and overall. In multivariable modeling, the pain symptom severity score was significantly associated with pesticide use (Odds ratio (OR): 4.13, 95% confidence intervals (CI): 1.78–9.57) and taking PB pills (OR: 2.28, 95% CI: 1.02–5.09), and overall symptom severity was significantly associated with use of PB pills (OR: 2.41, 95% CI: 1.01–5.75). Conclusion: Decades after deployment, Gulf War veterans referred to a VA tertiary evaluation center report a high burden of chronic symptoms, many of which were associated with reported neurotoxicant exposures during the war.

25 November 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
JVJacqueline Vahey
Jacqueline Vahey
EGElizabeth Joanne Gifford
Elizabeth Joanne Gifford
KSKellie J. Sims
Kellie J. Sims
BCBlair Chesnut
Blair Chesnut
SBStephen H. Boyle
Stephen H. Boyle
EHElizabeth R. Hauser
Elizabeth R. Hauser
About 25–35% of United States veterans who fought in the 1990–1991 Gulf War report several moderate or severe chronic systemic symptoms, defined as Gulf War illness (GWI). Thirty years later, there is little consensus on the causes or biological underpinnings of GWI. The Gulf War Era Cohort and Biorepository (GWECB) was designed to investigate genetic and environmental associations with GWI and consists of 1343 veterans. We investigate candidate gene–toxicant interactions that may be associated with GWI based on prior associations found in human and animal model studies, focusing on SNPs in or near ACHE, BCHE, and PON1 genes to replicate results from prior studies. SOD1 was also considered as a candidate gene. CDC Severe GWI, the primary outcome, was observed in 26% of the 810 deployed veterans included in this study. The interaction between the candidate SNP rs662 and pyridostigmine bromide (PB) pills was found to be associated with CDC Severe GWI. Interactions between PB pill exposure and rs3917545, rs3917550, and rs2299255, all in high linkage disequilibrium in PON1, were also associated with respiratory symptoms. These SNPs could point toward biological pathways through which GWI may develop, which could lead to biomarkers to detect GWI or to better treatment options for veterans with GWI.

EGElizabeth Joanne Gifford
Elizabeth Joanne Gifford
SBStephen H. Boyle
Stephen H. Boyle
JVJacqueline Vahey
Jacqueline Vahey
KSKellie J. Sims
Kellie J. Sims
Jimmy Thomas EfirdJimmy Thomas Efird
Jimmy Thomas Efird
EHElizabeth Hauser
Elizabeth Hauser
This study examines how health-related quality of life (HRQOL) and related indices vary by Gulf War illness (GWI) case status. The study population included veterans from the Gulf War Era Cohort and Biorepository (n = 1116). Outcomes were physical and mental health from the Veterans RAND 12 and depression, post-traumatic stress (PTSD), sleep disturbance, and pain. Kansas (KS) and Centers for Disease Control and Prevention (CDC) GWI definitions were used. Kansas GWI derived subtypes included GWI (met symptom criteria; no exclusionary conditions (KS GWI: Sym+/Dx−)) and those without GWI: KS noncase (1): Sym+/Dx+, KS noncase (2): Sym−/Dx+, and noncase (3): Sym−/Dx−. CDC-derived subtypes included CDC GWI severe, CDC GWI mild-to-moderate and CDC noncases. Case status and outcomes were examined using multivariable regression adjusted for sociodemographic and military-related characteristics. Logistic regression analysis was used to examine associations between GWI case status and binary measures for depression, PTSD, and severe pain. The KS GWI: Sym+/Dx− and KS noncase (1): Sym+/Dx+ groups had worse mental and physical HRQOL outcomes than veterans in the KS noncase (2): Sym−/Dx+ and KS noncase (3): Sym−/Dx− groups (ps < 0.001). Individuals who met the CDC GWI severe criteria had worse mental and physical HRQOL outcomes than those meeting the CDC GWI mild-to-moderate or CDC noncases (ps < 0.001). For other outcomes, results followed a similar pattern. Relative to the less symptomatic comparison subtypes, veterans who met the Kansas symptom criteria, regardless of exclusionary conditions, and those who met the CDC GWI severe criteria experienced lower HRQOL and higher rates of depression, PTSD, and severe pain.

1 December 2021 in Life Sciences
Verified
Journal Article
Closed access
MGMary E. Grewe
Mary E. Grewe
LKLara Khalil
Lara Khalil
KFKristina Felder
Kristina Felder
KGKaren M. Goldstein
Karen M. Goldstein
RMRebecca B. McNeil
Rebecca B. McNeil
CVCorrine I. Voils
Corrine I. Voils